Key facts
- This page summarizes Matthew Ronsheim's Form 4 filing for Innoviva, Inc. (INVA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Jan 2024, 21:16.
Matthew Ronsheim - 18 Jan 2024 Form 4 Insider Report for Innoviva, Inc. (INVA)
- Reporting relationship
- Officer
- Issuer ticker
- INVA
- Reported as of
- 18 Jan 2024
- Net transaction value
- -$25,680
- SEC form
- 4
- Accepted by SEC
- 22 Jan 2024, 21:16:54 UTC
- Prior SEC filing
- 10 Jan 2024
- Next SEC filing
- 22 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Ronsheim
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew Ronsheim filed Form 4 for Innoviva, Inc. (INVA) on 22 Jan 2024.
Change
- Previous filing in this sequence was filed on 10 Jan 2024.
- Current net transaction value: -$25,680.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INVA
transaction
Common Stock
Tax liability
- Transaction value
- $25,680
- Shares
- -1,600
- Change %
- -5.3%
- Price
- $16.05
- Shares after
- 28,817
- Date
- 18 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INVA
transaction
Derivative
Nonqualified Stock Option
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- +181%
- Price
- $0.000000
- Shares after
- 93,100
- Date
- 18 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $16.05
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
Footnote F2
25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Ronsheim's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Ronsheim experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Ronsheim for "good reason" (each as defined in Dr. Ronsheim's employment agreement) within 24 months following a "change in control," subject to an effective release of claims.
SEC remarks
Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.